{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T03:24:12Z","timestamp":1771039452658,"version":"3.50.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Natural Science Foundation of Fujian Province,China","award":["2024J08317"],"award-info":[{"award-number":["2024J08317"]}]},{"name":"Health science and technology project of Fujian Province","award":["2024QNB012"],"award-info":[{"award-number":["2024QNB012"]}]},{"name":"Talent Introduction Research Foundation of the First Affiliated Hospital of Xiamen University","award":["XYJ2023004"],"award-info":[{"award-number":["XYJ2023004"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s12035-025-05440-0","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T06:37:36Z","timestamp":1763707056000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Exploring the Role of B-Cell Biotherapy in Myasthenia Gravis from a Genetic Perspective: A Mendelian Randomization Study"],"prefix":"10.1007","volume":"63","author":[{"given":"Mengyuan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cen","family":"Yue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiahui","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caihong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caili","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanli","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingkai","family":"An","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiawei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"5440_CR1","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","volume":"8","author":"MN Meriggioli","year":"2009","unstructured":"Meriggioli MN, Sanders DB (2009) Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 8:475\u2013490. https:\/\/doi.org\/10.1016\/S1474-4422(09)70063-8","journal-title":"Lancet Neurol"},{"key":"5440_CR2","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1097\/WCO.0b013e3283572588","volume":"25","author":"NE Gilhus","year":"2012","unstructured":"Gilhus NE (2012) Myasthenia and the neuromuscular junction. Curr Opin Neurol 25:523\u2013529. https:\/\/doi.org\/10.1097\/WCO.0b013e3283572588","journal-title":"Curr Opin Neurol"},{"key":"5440_CR3","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.nmd.2019.07.006","volume":"29","author":"RHP de Meel","year":"2019","unstructured":"de Meel RHP, Tannemaat MR, Verschuuren JJGM (2019) Heterogeneity and shifts in distribution of muscle weakness in myasthenia gravis. Neuromuscul Disord 29:664\u2013670. https:\/\/doi.org\/10.1016\/j.nmd.2019.07.006","journal-title":"Neuromuscul Disord"},{"key":"5440_CR4","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S1474-4422(21)00297-0","volume":"21","author":"AR Punga","year":"2022","unstructured":"Punga AR, Maddison P, Heckmann JM et al (2022) Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders. Lancet Neurol 21:176\u2013188. https:\/\/doi.org\/10.1016\/S1474-4422(21)00297-0","journal-title":"Lancet Neurol"},{"key":"5440_CR5","doi-asserted-by":"publisher","unstructured":"(2020) Myasthenic crisis demanding mechanical ventilation: a multicenter analysis of 250 cases. Neurology 94:724. https:\/\/doi.org\/10.1212\/WNL.0000000000009262","DOI":"10.1212\/WNL.0000000000009262"},{"key":"5440_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00776","volume":"11","author":"ML Fichtner","year":"2020","unstructured":"Fichtner ML, Jiang R, Bourke A et al (2020) Autoimmune pathology in myasthenia gravis disease subtypes is governed by divergent mechanisms of immunopathology. Front Immunol 11:776. https:\/\/doi.org\/10.3389\/fimmu.2020.00776","journal-title":"Front Immunol"},{"key":"5440_CR7","doi-asserted-by":"publisher","unstructured":"Nowak RJ, Coffey CS, Goldstein JM et al (2022) Phase 2 trial of rituximab in acetylcholine receptor antibody-positive generalized myasthenia gravis: the BeatMG study. Neurology 98. https:\/\/doi.org\/10.1212\/WNL.0000000000013121","DOI":"10.1212\/WNL.0000000000013121"},{"key":"5440_CR8","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M et al (2016) International consensus guidance for management of myasthenia gravis: executive summary. Neurology 87:419\u2013425. https:\/\/doi.org\/10.1212\/WNL.0000000000002790","journal-title":"Neurology"},{"key":"5440_CR9","doi-asserted-by":"publisher","DOI":"10.1177\/1756285617749134","volume":"11","author":"R Mantegazza","year":"2018","unstructured":"Mantegazza R, Antozzi C (2018) When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies. Ther Adv Neurol Disord 11:1756285617749134. https:\/\/doi.org\/10.1177\/1756285617749134","journal-title":"Ther Adv Neurol Disord"},{"key":"5440_CR10","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1001\/jamaneurol.2020.0851","volume":"77","author":"S Brauner","year":"2020","unstructured":"Brauner S, Eriksson-Dufva A, Hietala MA et al (2020) Comparison between rituximab treatment for new-onset generalized myasthenia gravis and refractory generalized myasthenia gravis. JAMA Neurol 77:974. https:\/\/doi.org\/10.1001\/jamaneurol.2020.0851","journal-title":"JAMA Neurol"},{"key":"5440_CR11","doi-asserted-by":"publisher","first-page":"e376","DOI":"10.1212\/WNL.0000000000013121","volume":"98","author":"RJ Nowak","year":"2022","unstructured":"Nowak RJ, Coffey CS, Goldstein JM et al (2022) Phase 2 trial of Rituximab in acetylcholine receptor antibody-positive generalized myasthenia gravis. Neurology 98:e376\u2013e389. https:\/\/doi.org\/10.1212\/WNL.0000000000013121","journal-title":"Neurology"},{"key":"5440_CR12","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1001\/jama.2017.17219","volume":"318","author":"CA Emdin","year":"2017","unstructured":"Emdin CA, Khera AV, Kathiresan S (2017) Mendelian randomization. JAMA 318:1925. https:\/\/doi.org\/10.1001\/jama.2017.17219","journal-title":"JAMA"},{"key":"5440_CR13","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a041302","volume":"12","author":"E Birney","year":"2022","unstructured":"Birney E (2022) Mendelian randomization. Cold Spring Harb Perspect Med 12:a041302. https:\/\/doi.org\/10.1101\/cshperspect.a041302","journal-title":"Cold Spring Harb Perspect Med"},{"key":"5440_CR14","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1093\/brain\/awab420","volume":"145","author":"TH Julian","year":"2022","unstructured":"Julian TH, Boddy S, Islam M et al (2022) A review of Mendelian randomization in amyotrophic lateral sclerosis. Brain 145:832\u2013842. https:\/\/doi.org\/10.1093\/brain\/awab420","journal-title":"Brain"},{"key":"5440_CR15","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1038\/s41588-020-0684-4","volume":"52","author":"V Orr\u00f9","year":"2020","unstructured":"Orr\u00f9 V, Steri M, Sidore C et al (2020) Complex genetic signatures in immune cells underlie autoimmunity and inform therapy. Nat Genet 52:1036\u20131045. https:\/\/doi.org\/10.1038\/s41588-020-0684-4","journal-title":"Nat Genet"},{"key":"5440_CR16","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2108672119","volume":"119","author":"R Chia","year":"2022","unstructured":"Chia R, Saez-Atienzar S, Murphy N et al (2022) Identification of genetic risk loci and prioritization of genes and pathways for myasthenia gravis: a genome-wide association study. Proc Natl Acad Sci USA 119:e2108672119. https:\/\/doi.org\/10.1073\/pnas.2108672119","journal-title":"Proc Natl Acad Sci USA"},{"key":"5440_CR17","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/ng.3211","volume":"47","author":"BK Bulik-Sullivan","year":"2015","unstructured":"Bulik-Sullivan BK, Loh P-R, Finucane HK et al (2015) LD score regression distinguishes confounding from polygenicity in genome-wide association studies. Nat Genet 47:291\u2013295. https:\/\/doi.org\/10.1038\/ng.3211","journal-title":"Nat Genet"},{"key":"5440_CR18","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s10654-015-0011-z","volume":"30","author":"S Burgess","year":"2015","unstructured":"Burgess S, Scott RA, Timpson NJ et al (2015) Using published data in Mendelian randomization: a blueprint for efficient identification of causal risk factors. Eur J Epidemiol 30:543\u2013552. https:\/\/doi.org\/10.1007\/s10654-015-0011-z","journal-title":"Eur J Epidemiol"},{"key":"5440_CR19","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1093\/ije\/dyx034","volume":"46","author":"OO Yavorska","year":"2017","unstructured":"Yavorska OO, Burgess S (2017) Mendelianrandomization: an R package for performing Mendelian randomization analyses using summarized data. Int J Epidemiol 46:1734\u20131739. https:\/\/doi.org\/10.1093\/ije\/dyx034","journal-title":"Int J Epidemiol"},{"key":"5440_CR20","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/gepi.21758","volume":"37","author":"S Burgess","year":"2013","unstructured":"Burgess S, Butterworth A, Thompson SG (2013) Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol 37:658\u2013665. https:\/\/doi.org\/10.1002\/gepi.21758","journal-title":"Genet Epidemiol"},{"key":"5440_CR21","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13059-019-1716-1","volume":"20","author":"K Korthauer","year":"2019","unstructured":"Korthauer K, Kimes PK, Duvallet C et al (2019) A practical guide to methods controlling false discoveries in computational biology. Genome Biol 20:118. https:\/\/doi.org\/10.1186\/s13059-019-1716-1","journal-title":"Genome Biol"},{"key":"5440_CR22","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1002\/sim.6522","volume":"34","author":"MFD Greco","year":"2015","unstructured":"Greco MFD, Minelli C, Sheehan NA, Thompson JR (2015) Detecting pleiotropy in Mendelian randomisation studies with summary data and a continuous outcome. Stat Med 34:2926\u20132940. https:\/\/doi.org\/10.1002\/sim.6522","journal-title":"Stat Med"},{"key":"5440_CR23","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1093\/ije\/dyv080","volume":"44","author":"J Bowden","year":"2015","unstructured":"Bowden J, Davey Smith G, Burgess S (2015) Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol 44:512\u2013525. https:\/\/doi.org\/10.1093\/ije\/dyv080","journal-title":"Int J Epidemiol"},{"key":"5440_CR24","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41588-018-0099-7","volume":"50","author":"M Verbanck","year":"2018","unstructured":"Verbanck M, Chen C-Y, Neale B, Do R (2018) Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet 50:693\u2013698. https:\/\/doi.org\/10.1038\/s41588-018-0099-7","journal-title":"Nat Genet"},{"key":"5440_CR25","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1093\/ije\/dyx102","volume":"46","author":"FP Hartwig","year":"2017","unstructured":"Hartwig FP, Davey Smith G, Bowden J (2017) Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption. Int J Epidemiol 46:1985\u20131998. https:\/\/doi.org\/10.1093\/ije\/dyx102","journal-title":"Int J Epidemiol"},{"key":"5440_CR26","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/gepi.21965","volume":"40","author":"J Bowden","year":"2016","unstructured":"Bowden J, Davey Smith G, Haycock PC, Burgess S (2016) Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. Genet Epidemiol 40:304\u2013314. https:\/\/doi.org\/10.1002\/gepi.21965","journal-title":"Genet Epidemiol"},{"key":"5440_CR27","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1093\/aje\/kwu283","volume":"181","author":"S Burgess","year":"2015","unstructured":"Burgess S, Thompson SG (2015) Multivariable Mendelian randomization: the use of pleiotropic genetic variants to estimate causal effects. Am J Epidemiol 181:251\u2013260. https:\/\/doi.org\/10.1093\/aje\/kwu283","journal-title":"Am J Epidemiol"},{"key":"5440_CR28","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1093\/ije\/dyy262","volume":"48","author":"E Sanderson","year":"2019","unstructured":"Sanderson E, Davey Smith G, Windmeijer F, Bowden J (2019) An examination of multivariable Mendelian randomization in the single-sample and two-sample summary data settings. Int J Epidemiol 48:713\u2013727. https:\/\/doi.org\/10.1093\/ije\/dyy262","journal-title":"Int J Epidemiol"},{"key":"5440_CR29","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.ajhg.2022.04.001","volume":"109","author":"RJ Nowak","year":"2022","unstructured":"Nowak RJ, Coffey CS, Goldstein JM et al (2022) Combining evidence from Mendelian randomization and colocalization: Review and comparison of approaches. The American Journal of Human Genetics 109:767\u2013782. https:\/\/doi.org\/10.1016\/j.ajhg.2022.04.001","journal-title":"The American Journal of Human Genetics"},{"key":"5440_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1008720","volume":"16","author":"C Wallace","year":"2005","unstructured":"Wallace C (2005) Eliciting priors and relaxing the single causal variant assumption in colocalisation analyses. PLoS Genet 16:e1008720. https:\/\/doi.org\/10.1371\/journal.pgen.1008720","journal-title":"PLoS Genet"},{"key":"5440_CR31","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jamadermatol.2022.6051","volume":"159","author":"SS Zhao","year":"2023","unstructured":"Zhao SS, Yiu ZZN, Barton A, Bowes J (2023) Association of lipid-lowering drugs with risk of psoriasis. JAMA Dermatol 159:275. https:\/\/doi.org\/10.1001\/jamadermatol.2022.6051","journal-title":"JAMA Dermatol"},{"key":"5440_CR32","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000001814","author":"Y Lu","year":"2015","unstructured":"Lu Y, Yao Y, Zhai S et al (2015) The role of immune cell signatures in the pathogenesis of ovarian-related diseases: a causal inference based on mendelian randomization. Int J Surg. https:\/\/doi.org\/10.1097\/JS9.0000000000001814","journal-title":"Int J Surg"},{"key":"5440_CR33","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1038\/s41588-019-0404-0","volume":"51","author":"B Liu","year":"2019","unstructured":"Liu B, Gloudemans MJ, Rao AS et al (2019) Abundant associations with gene expression complicate GWAS follow-up. Nat Genet 51:768\u2013769. https:\/\/doi.org\/10.1038\/s41588-019-0404-0","journal-title":"Nat Genet"},{"key":"5440_CR34","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/159499a0","volume":"159","author":"A Fagraeus","year":"1947","unstructured":"Fagraeus A (1947) Plasma cellular reaction and its relation to the formation of antibodies in vitro. Nature 159:499\u2013499. https:\/\/doi.org\/10.1038\/159499a0","journal-title":"Nature"},{"key":"5440_CR35","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.immuni.2020.11.006","volume":"53","author":"RA Elsner","year":"2020","unstructured":"Elsner RA, Shlomchik MJ (2020) Germinal center and extrafollicular B cell responses in vaccination, immunity, and autoimmunity. Immunity 53:1136\u20131150. https:\/\/doi.org\/10.1016\/j.immuni.2020.11.006","journal-title":"Immunity"},{"key":"5440_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.725700","volume":"12","author":"X Feng","year":"2021","unstructured":"Feng X, Song Z, Wu M et al (2021) Efficacy and safety of immunotherapies in refractory myasthenia gravis: a systematic review and meta-analysis. Front Neurol 12:725700. https:\/\/doi.org\/10.3389\/fneur.2021.725700","journal-title":"Front Neurol"},{"key":"5440_CR37","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1111\/ene.14391","volume":"27","author":"A Dos Santos","year":"2020","unstructured":"Dos Santos A, Noury J-B, Genestet S et al (2020) Efficacy and safety of rituximab in myasthenia gravis: a French multicentre real-life study. Euro J of Neurology 27:2277\u20132285. https:\/\/doi.org\/10.1111\/ene.14391","journal-title":"Euro J of Neurology"},{"key":"5440_CR38","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1182\/blood.V70.5.1316.1316","volume":"70","author":"MR Loken","year":"1987","unstructured":"Loken MR, Shah VO, Dattilio KL, Civin CI (1987) Flow cytometric analysis of human bone marrow. II. Normal B lymphocyte development. Blood 70:1316\u20131324","journal-title":"Blood"},{"key":"5440_CR39","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.4049\/jimmunol.125.4.1678","volume":"125","author":"P Stashenko","year":"1980","unstructured":"Stashenko P, Nadler LM, Hardy R, Schlossman SF (1980) Characterization of a human B lymphocyte-specific antigen. J Immunol 125:1678\u20131685. https:\/\/doi.org\/10.4049\/jimmunol.125.4.1678","journal-title":"J Immunol"},{"key":"5440_CR40","doi-asserted-by":"publisher","first-page":"3848","DOI":"10.1073\/pnas.78.6.3848","volume":"78","author":"RJ Nowak","year":"1981","unstructured":"Nowak RJ, Coffey CS, Goldstein JM et al (1981) Expression of cell surface markers after human B lymphocyte activation. Proc Natl Acad Sci USA 78:3848\u20133852. https:\/\/doi.org\/10.1073\/pnas.78.6.3848","journal-title":"Proc Natl Acad Sci USA"},{"key":"5440_CR41","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jaci.2013.01.046","volume":"131","author":"K Pieper","year":"2013","unstructured":"Pieper K, Grimbacher B, Eibel H (2013) B-cell biology and development. J Allergy Clin Immunol 131:959\u2013971. https:\/\/doi.org\/10.1016\/j.jaci.2013.01.046","journal-title":"J Allergy Clin Immunol"},{"key":"5440_CR42","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1038\/sj.leu.2402639","volume":"16","author":"C Kosmas","year":"2002","unstructured":"Kosmas C, Stamatopoulos K, Stavroyianni N et al (2002) Anti-CD20-based therapy of B cell lymphoma: state of the art. Leukemia 16:2004\u20132015. https:\/\/doi.org\/10.1038\/sj.leu.2402639","journal-title":"Leukemia"},{"key":"5440_CR43","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41573-020-00092-2","volume":"20","author":"DSW Lee","year":"2021","unstructured":"Lee DSW, Rojas OL, Gommerman JL (2021) B cell depletion therapies in autoimmune disease: advances and mechanistic insights. Nat Rev Drug Discov 20:179\u2013199. https:\/\/doi.org\/10.1038\/s41573-020-00092-2","journal-title":"Nat Rev Drug Discov"},{"key":"5440_CR44","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1136\/practneurol-2018-001899","volume":"19","author":"DH Whittam","year":"2019","unstructured":"Whittam DH, Tallantyre EC, Jolles S et al (2019) Rituximab in neurological disease: principles, evidence and practice. Pract Neurol 19:5\u201320. https:\/\/doi.org\/10.1136\/practneurol-2018-001899","journal-title":"Pract Neurol"},{"key":"5440_CR45","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s00415-014-7532-3","volume":"262","author":"R Iorio","year":"2015","unstructured":"Iorio R, Damato V, Alboini PE, Evoli A (2015) Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis. J Neurol 262:1115\u20131119. https:\/\/doi.org\/10.1007\/s00415-014-7532-3","journal-title":"J Neurol"},{"key":"5440_CR46","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/j.1600-065X.2010.00929.x","volume":"237","author":"K Chen","year":"2010","unstructured":"Chen K, Cerutti A (2010) New insights into the enigma of immunoglobulin D. Immunol Rev 237:160\u2013179. https:\/\/doi.org\/10.1111\/j.1600-065X.2010.00929.x","journal-title":"Immunol Rev"},{"key":"5440_CR47","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1189\/jlb.1002492","volume":"73","author":"SML Tamma","year":"2003","unstructured":"Tamma SML, Coico RF (2003) IgD-receptor (IgD-R) cross-linking partially protects murine T cells from dexamethasone-induced apoptosis. J Leukoc Biol 73:764\u2013770. https:\/\/doi.org\/10.1189\/jlb.1002492","journal-title":"J Leukoc Biol"},{"key":"5440_CR48","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/nrm1736","volume":"6","author":"ME Hemler","year":"2005","unstructured":"Hemler ME (2005) Tetraspanin functions and associated microdomains. Nat Rev Mol Cell Biol 6:801\u2013811. https:\/\/doi.org\/10.1038\/nrm1736","journal-title":"Nat Rev Mol Cell Biol"},{"key":"5440_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01185","volume":"9","author":"F Schaper","year":"2018","unstructured":"Schaper F, van Spriel AB (2018) Antitumor immunity is controlled by tetraspanin proteins. Front Immunol 9:1185. https:\/\/doi.org\/10.3389\/fimmu.2018.01185","journal-title":"Front Immunol"},{"key":"5440_CR50","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2024.2362454","volume":"13","author":"M Bobrowicz","year":"2024","unstructured":"Bobrowicz M, Kusowska A, Krawczyk M et al (2024) CD20 expression regulates CD37 levels in B-cell lymphoma \u2013 implications for immunotherapies. Oncoimmunology 13:2362454. https:\/\/doi.org\/10.1080\/2162402X.2024.2362454","journal-title":"Oncoimmunology"},{"key":"5440_CR51","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1182\/blood-2016-05-715094","volume":"128","author":"ZY Xu-Monette","year":"2016","unstructured":"Xu-Monette ZY, Li L, Byrd JC et al (2016) Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma. Blood 128:3083\u20133100. https:\/\/doi.org\/10.1182\/blood-2016-05-715094","journal-title":"Blood"},{"key":"5440_CR52","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1182\/blood.V126.23.1258.1258","volume":"126","author":"KA Beckwith","year":"2015","unstructured":"Beckwith KA, Williams EI, Wright MD et al (2015) The role of tetraspanin CD37 in B-cell malignancy. Blood 126:1258\u20131258. https:\/\/doi.org\/10.1182\/blood.V126.23.1258.1258","journal-title":"Blood"},{"key":"5440_CR53","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1182\/blood-2011-08-372268","volume":"118","author":"IW Flinn","year":"2011","unstructured":"Flinn IW (2011) CD37: the comeback kid. Blood 118:4007\u20134008. https:\/\/doi.org\/10.1182\/blood-2011-08-372268","journal-title":"Blood"},{"key":"5440_CR54","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1080\/13543784.2018.1427730","volume":"27","author":"M Witkowska","year":"2018","unstructured":"Witkowska M, Smolewski P, Robak T (2018) Investigational therapies targeting CD37 for the treatment of B-cell lymphoid malignancies. Expert Opin Investig Drugs 27:171\u2013177. https:\/\/doi.org\/10.1080\/13543784.2018.1427730","journal-title":"Expert Opin Investig Drugs"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-025-05440-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-025-05440-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-025-05440-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T06:37:37Z","timestamp":1763707057000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-025-05440-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["5440"],"URL":"https:\/\/doi.org\/10.1007\/s12035-025-05440-0","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"18 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The GWAS summary data on B cell immunophenotype and myasthenia gravis were derived from published studies; therefore, no additional ethical approval was required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"All the authors agreed to publish this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"115"}}